Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer

2021 ◽  
Vol 41 (4) ◽  
pp. 2133-2140
Author(s):  
RITSUKO SASAKI ◽  
YOSHIYA HORIMOTO ◽  
YUKA YANAI ◽  
AIKO KURISAKI-ARAKAWA ◽  
ATSUSHI ARAKAWA ◽  
...  
Author(s):  
Ding Ma ◽  
Si-Yu Chen ◽  
Jin-Xiao Ren ◽  
Yu-Chen Pei ◽  
Cong-Wei Jiang ◽  
...  

Abstract Background The germline variant spectrum of triple-negative breast cancer (TNBC) is different from that of other subtypes and has demonstrated ethnic differences. However, the germline variants of TNBC among Chinese patients and its clinical significance remain unclear. Methods Using our multi-omics TNBC cohort (n = 325), we determined the spectrum of germline variants in TNBC and aimed to illustrate their biological and clinical implications. Results Overall, 16.0% (52 of 325) of TNBC patients harbored at least 1 pathogenic or likely pathogenic germline variant. These germline variants were associated with early onset of TNBC, the occurrence of contralateral breast cancer, the basal-like immune-suppressed mRNA subtype, and the homologous recombination deficiency (HRD) mutation subtype. Somatic allele-specific imbalance was observed in 54.1% of these germline variants, which was correlated with early onset of breast cancer and elevated HRD. The genes BRCA1 (7.4%), RAD51D (2.8%), and BRCA2 (2.2%) were those most frequently mutated. The RAD51D germline variants, especially K91fs, were enriched in Chinese patients with TNBC compared with Caucasian and African American patients. The Chinese-specific RAD51D germline variants were functionally associated with the instability of the RAD51D protein, HRD, and sensitivity to PARP inhibitors. Conclusions Chinese TNBC patients have a distinct spectrum of germline variants, with a remarkable impact on the clinical and molecular characteristics of the tumor. Integrative germline-somatic analysis may help identify TNBC patients who are most likely to be affected by their germline variants and in performing clinical interventions more precisely. The RAD51D variants enriched in our cohort may serve as therapeutic targets and guide precision treatment of TNBC.


2015 ◽  
Vol 12 (5) ◽  
pp. 7326-7334 ◽  
Author(s):  
CHUNG-HSIN TSAI ◽  
JEN-HWEY CHIU ◽  
CHU-WEN YANG ◽  
JIR-YOU WANG ◽  
YI-FANG TSAI ◽  
...  

Breast Cancer ◽  
2021 ◽  
Author(s):  
Juan Zhang ◽  
Qi Tian ◽  
Mi Zhang ◽  
Hui Wang ◽  
Lei Wu ◽  
...  

AbstractBreast cancer is a commonly diagnosed female cancer in the world. Triple-negative breast cancer (TNBC) is the most dangerous and biologically aggressive subtype in breast cancer which has a high mortality, high rates of relapse and poor prognosis, representing approximately 15–20% of breast cancers. TNBC has unique and special biological molecular characteristics and higher immunogenicity than other breast cancer types. On the basis of molecular features, TNBC is divided into different subtypes and gets various treatments. Especially, immunotherapy becomes a promising and effective treatment to TNBC. However, not all of the TNBC patients are sensitive to immunotherapy, the need of selecting the patients suitable for immunotherapy is imperative. In this review, we discussed recent discoveries about the immune-related factors of TNBC, including tumor-infiltrating lymphocytes (TILs), programmed death-ligand protein-1 (PD-L1), immune gene signatures, some other emerging biomarkers for immunotherapy effectivity and promising biomarkers for immunotherapy resistance. In addition, we summarized the features of these biomarkers contributing to predict the prognosis and effect of immunotherapy. We hope we can provide some helps or evidences to clinical immunotherapy and combined treatment for TNBC patients.


PLoS ONE ◽  
2012 ◽  
Vol 7 (9) ◽  
pp. e45831 ◽  
Author(s):  
Wen-Hung Kuo ◽  
Yao-Yin Chang ◽  
Liang-Chuan Lai ◽  
Mong-Hsun Tsai ◽  
Chuhsing Kate Hsiao ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document